ATE190657T1 - Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa - Google Patents

Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa

Info

Publication number
ATE190657T1
ATE190657T1 AT95118098T AT95118098T ATE190657T1 AT E190657 T1 ATE190657 T1 AT E190657T1 AT 95118098 T AT95118098 T AT 95118098T AT 95118098 T AT95118098 T AT 95118098T AT E190657 T1 ATE190657 T1 AT E190657T1
Authority
AT
Austria
Prior art keywords
pseudomonas aeruginosa
hybrid protein
oprl
available
membrane proteins
Prior art date
Application number
AT95118098T
Other languages
English (en)
Inventor
Bernhard Dr Knapp
Klaus-Dieter Dr Hungerer
Michael Dr Broeker
Specht Bernd Ulrich Prof Von
Horst Prof Domdey
Original Assignee
Chiron Behring Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Behring Gmbh & Co filed Critical Chiron Behring Gmbh & Co
Application granted granted Critical
Publication of ATE190657T1 publication Critical patent/ATE190657T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/824—Bacterial vaccine for ovine species, e.g. sheep
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT95118098T 1994-12-16 1995-11-17 Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa ATE190657T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94120023 1994-12-16

Publications (1)

Publication Number Publication Date
ATE190657T1 true ATE190657T1 (de) 2000-04-15

Family

ID=8216542

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95118098T ATE190657T1 (de) 1994-12-16 1995-11-17 Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa

Country Status (8)

Country Link
US (2) US5955090A (de)
EP (1) EP0717106B1 (de)
JP (2) JP3712244B2 (de)
KR (1) KR960022559A (de)
AT (1) ATE190657T1 (de)
AU (1) AU4041995A (de)
CA (1) CA2165401C (de)
DE (1) DE69515613T2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207538T1 (de) * 1995-02-09 2001-11-15 Behringwerke Ag Verfahren zur produktion von proteinen
GB9701489D0 (en) 1997-01-24 1997-03-12 Auspharm Int Ltd Antigen
KR100461710B1 (ko) * 1997-09-13 2005-09-28 씨제이 주식회사 신규한 녹농균 세포 외막 단백질 유전자 및 이를 이용한 녹농균 감염 예방용 백신 및 녹농균 감염증 치료제
GB9915044D0 (en) * 1999-06-25 1999-08-25 Smithkline Beecham Biolog Novel compounds
EP1078988A1 (de) * 1999-08-27 2001-02-28 Academia Sinica Pseudomonas Fusionsprotein-Impstoff
EP1255562B1 (de) * 2000-02-18 2008-01-16 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene
CN1484700A (zh) * 2000-11-02 2004-03-24 �¼��¹�����ѧ aopB基因,蛋白,同系物,片段和它们的变体,以及它们在细胞表面展示方面的应用
JP2002316944A (ja) * 2001-04-17 2002-10-31 Chemo Sero Therapeut Res Inst ヒトポリクローナル抗体組成物
EP1790659B1 (de) 2001-11-13 2013-07-31 ID Biomedical Corporation Pseudomonas aeruginosa Polypeptide
ES2431318T3 (es) * 2001-11-13 2013-11-26 Id Biomedical Corporation Polipéptidos de Pseudomonas aeruginosa
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
EP1499712A4 (de) 2002-04-12 2008-04-16 Melbourne Health Hepatitis-b-virusvarianten mit verminderter empfindlichkeit gegenüber nukleosidanalogen und verwendung davon
EP1874923A4 (de) 2005-04-08 2010-08-04 Melbourne Health Varianten des hepatitis-b-virus mit resistenz gegenüber antiviralen nukleosidagentien und anwendungen davon
US8211443B2 (en) 2005-04-08 2012-07-03 Melbourne Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
JPWO2007049770A1 (ja) 2005-10-28 2009-04-30 明治製菓株式会社 緑膿菌の外膜タンパク質ｐａ５１５８
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
KR20080113239A (ko) 2006-03-30 2008-12-29 메이지 세이카 가부시키가이샤 녹농균의 외막 단백질 ｐａ0427
CA2691626A1 (en) * 2007-06-29 2009-01-08 Jiro Tanaka Pseudomonas aeruginosa-outer membrane protein pa4710
US20100291070A1 (en) * 2007-12-25 2010-11-18 Meiji Seika Kaisha, Ltd. Type iii secretion system component protein pa1698 of pseudomonas aeruginosa
EP2408475B1 (de) 2009-03-18 2017-11-15 Wake Forest University Health Sciences Flagellin-fusionsproteine und ihre verwendung zur auslösung von immunantworten gegen pseudomonas aeruginosa
CA2822684A1 (en) 2010-12-23 2012-06-28 Intercell Austria Ag Oprf/i agents and their use in hospitalized and other patients
WO2012126879A1 (en) * 2011-03-18 2012-09-27 Intercell Ag Novel oprf/i fusion proteins, their preparation and use
RU2529359C2 (ru) * 2012-09-19 2014-09-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" Российской академии медицинских наук (ФГБУ "НИИВС им. И.И. Мечникова" РАМН) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPA-OPRF-ETA, КОДИРУЮЩАЯ СИНТЕЗ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa, ШТАММ Escherichia coli PA-OPRF-ETA - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa И СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО БЕЛКА OPRF-ETA Pseudomonas aeruginosa
CN105142666A (zh) 2012-11-30 2015-12-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
WO2016033547A1 (en) * 2014-08-29 2016-03-03 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and oprl
WO2016193402A1 (en) * 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
EP4116316A1 (de) 2015-07-04 2023-01-11 Evaxion Biotech A/S Proteine und nukleinsäuren, die in impfstoffen gegen pseudomonas aeruginosa nützlich sind
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718591A1 (de) * 1987-06-03 1988-12-15 Behringwerke Ag Aeusseres membranprotein f von pseudomonas aeruginosa
DE3829616C2 (de) * 1988-09-01 1996-08-29 Behringwerke Ag Lipoprotein I (OMPI) von Pseudomonas aeruginosa
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
WO1993024636A1 (en) * 1992-05-29 1993-12-09 The University Of British Columbia Use of protein oprf for bacterial cell surface expression of oligopeptides

Also Published As

Publication number Publication date
DE69515613D1 (de) 2000-04-20
DE69515613T2 (de) 2000-11-30
EP0717106B1 (de) 2000-03-15
KR960022559A (ko) 1996-07-18
JP2005097321A (ja) 2005-04-14
JP3712244B2 (ja) 2005-11-02
AU4041995A (en) 1996-06-27
JPH08245699A (ja) 1996-09-24
US5955090A (en) 1999-09-21
US6300102B1 (en) 2001-10-09
JP3762779B2 (ja) 2006-04-05
CA2165401A1 (en) 1996-06-17
EP0717106A1 (de) 1996-06-19
CA2165401C (en) 2010-05-11

Similar Documents

Publication Publication Date Title
DE69515613D1 (de) Immunogenes Hybridprotein OprF-Oprl erhältlich aus Membranproteinen von Pseudomonas aeruginosa
ATE430200T1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
DE69535795D1 (de) Polynukleinsäuren und proteine aus einem "porcine reproductive and respiratory syndrome virus" und ihre verwendung
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
NO20003526D0 (no) Proteiner kodet av polynukleinsyrer fra svinereproduktive- og respiratoriske syndromvirus (PRRSV)
DK0617706T3 (da) Multivalente antigenbindende proteiner
DE60131456D1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
DK0821695T3 (da) Oprensning af antistof ved hydrofob interaktionschromatografi ved lav pH-værdi
ATE442866T1 (de) Fusionsproteine aus mycobakterium tuberculosis
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
DE59309458D1 (de) Synthetische Peptide, Antikörper dagegen und ihre Verwendung
DE59209921D1 (de) Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
ATE280227T1 (de) Epitope von stress proteinen
ATE47524T1 (de) Hundeparvovirus-impfstoffe.
ATE342920T1 (de) Methylierte smd homologe peptide, die mit antikörpern aus sera von lebewesen mit systemischer lupus erythematodes reagieren
ATE260977T1 (de) Immunoglobulin-bindende proteine
ATE230418T1 (de) Monoklonaler antikörper gegen das humane mx- protein mxa
AU7004894A (en) Synthetic peptides and vaccines against parvovirus
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
WO1996022372A3 (en) Antibodies for the control of cyst nematodes and transgenic plants expressing them
ES2114527T3 (es) Anticuerpos que reconocen especificamente la proteina de enlace de la somatotropina.
PT998493E (pt) Epitopos de toxina semelhante a shigella e a sua utilizacao como vacinas e em diagnosticos
EP0953642A4 (de) Antigenprotein aus infektiöse laryngotracheitis viren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification